EGFR and non-small cell lung carcinoma: Finally, the PROSE study (Table 2) randomized 285 unselected second-line NSCLC patients, who were blinded classified according to a serum proteomic algorithm (the VeriStrat® test), previously developed, with the aim to identify patients who could benefit from EGFR–TKIs (38, 41).